Form 4: Rapport Therapeutics COO Sells Shares After Option Exercise

Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, executed a pre-planned sale of 5,000 common shares following the exercise of stock options.

Summary

• Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, Inc., engaged in a pre-planned transaction on September 8, 2025.
• The transaction involved the exercise of stock options to acquire 5,000 shares of common stock at an exercise price of $1.80 per share.
• Immediately following the option exercise, 5,000 shares of common stock were sold at a price of $38.33 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 11, 2024.
• Following these transactions, Ms. Gault directly beneficially owns 171,928 shares of common stock.
• Ms. Gault also holds 110,407 stock options with an exercise price of $1.80, which began vesting on August 7, 2024, with remaining shares vesting in 36 equal monthly installments.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option exercise and sale) executed under a pre-planned 10b5-1 trading plan, which is generally considered neutral in terms of immediate sentiment impact.

Positives

• The option exercise and subsequent sale indicate a significant gain for the insider, as shares acquired at $1.80 were sold at $38.33.
• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled, non-discretionary sale, which can reduce concerns about opportunistic insider selling.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity stake of a key executive in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transactions involve an executive officer of Rapport Therapeutics, Inc., making them related party transactions by definition.

Stakeholder Impact

• Shareholders may view the sale as a reduction in insider ownership, though the pre-planned nature mitigates concerns.
• Employees are not directly impacted by this specific transaction report.

Key Dates

Recommendation

The Form 4 details a routine, pre-scheduled insider transaction (option exercise and sale) under a 10b5-1 plan. While it represents a reduction in direct equity holdings by a key executive, the pre-planned nature suggests it is not based on new, material non-public information. Therefore, it does not provide sufficient new information to warrant a change from a 'hold' position, assuming no other significant news is present.

Keywords

Rapport Therapeutics, RAPP, Cheryl Gault, Chief Operating Officer, COO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Equity Transaction